Abstract
Several oral direct anti-Xa agents and one antithrombin agent are currently under clinical development for the prevention and treatment of venous thromboembolism (VTE). The anti-Xa inhibitors rivaroxaban (10 mg once daily) and apixaban (2.5 mg twice daily) as well as the thrombin inhibitor dabigatran (150 or 220 mg once daily) have been recently licensed for the prevention of VTE in total hip or knee replacement. The publication of the results of studies with rivaroxaban and apixaban in the prevention of VTE in medical patients are awaited.
Phase III studies on the treatment of VTE showed the non inferiority of rivaroxaban (15 mg twice daily in the first three weeks and 20 mg once daily thereafter) and dabigatran (150 mg twice daily) to standard treatment. The incidence of major or clinically relevant non-major bleeding was similar in patients receiving standard treatment and rivaroxaban or dabigatran. Clinical trials on VTE treatment are currently ongoing with apixaban and edoxaban.
A number of phase II clinical trials are currently ongoing with several other antiXa agents in the prophylaxis and treatment of VTE.
Keywords: Anticoagulant therapy, antithrombotic therapy, anticoagulants, direct thrombin inhibitors, Factor Xa inhibitors
Current Drug Discovery Technologies
Title:New Oral Anticoagulants for Venous Thromboembolism: Focus on Factor Xa and Thrombin Inhibitors
Volume: 9 Issue: 2
Author(s): Cecilia Becattini, Alessandra Lignani and Giancarlo Agnelli
Affiliation:
Keywords: Anticoagulant therapy, antithrombotic therapy, anticoagulants, direct thrombin inhibitors, Factor Xa inhibitors
Abstract: Several oral direct anti-Xa agents and one antithrombin agent are currently under clinical development for the prevention and treatment of venous thromboembolism (VTE). The anti-Xa inhibitors rivaroxaban (10 mg once daily) and apixaban (2.5 mg twice daily) as well as the thrombin inhibitor dabigatran (150 or 220 mg once daily) have been recently licensed for the prevention of VTE in total hip or knee replacement. The publication of the results of studies with rivaroxaban and apixaban in the prevention of VTE in medical patients are awaited.
Phase III studies on the treatment of VTE showed the non inferiority of rivaroxaban (15 mg twice daily in the first three weeks and 20 mg once daily thereafter) and dabigatran (150 mg twice daily) to standard treatment. The incidence of major or clinically relevant non-major bleeding was similar in patients receiving standard treatment and rivaroxaban or dabigatran. Clinical trials on VTE treatment are currently ongoing with apixaban and edoxaban.
A number of phase II clinical trials are currently ongoing with several other antiXa agents in the prophylaxis and treatment of VTE.
Export Options
About this article
Cite this article as:
Becattini Cecilia, Lignani Alessandra and Agnelli Giancarlo, New Oral Anticoagulants for Venous Thromboembolism: Focus on Factor Xa and Thrombin Inhibitors, Current Drug Discovery Technologies 2012; 9 (2) . https://dx.doi.org/10.2174/1570163811209020119
DOI https://dx.doi.org/10.2174/1570163811209020119 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: News in Cardiovascular Surgery Treatment: Is there Anything to do Before and After it?
Current Vascular Pharmacology Progress in Spectroscopic Probes with Cleavable Active Bonds
Current Organic Chemistry Morphological and Histopathological Study of Autopsied Patients with Atherosclerosis and HIV
Current HIV Research Hemodynamic Monitoring in the Acute Management of Pediatric Heart Failure
Current Cardiology Reviews Structure-Based Virtual Screening to Identify Negative Allosteric Modulators of NMDA
Medicinal Chemistry Neglected Aspects of Drug Discovery - Microbiological Aspects
Current Clinical Pharmacology Editorial (Thematic Issue: Cardiac Imaging in the Diagnosis of Coronary Artery Disease: A Comprehensive Overview of Various Imaging Modalities)
Current Medical Imaging Meet Our Associate Editor:
Cardiovascular & Hematological Disorders-Drug Targets Part 1: The Wider Considerations in Translating Heart Failure Guidelines
Current Cardiology Reviews PCSK9 and Inflammation: Their Role in Autoimmune Diseases, with a Focus on Rheumatoid Arthritis and Systemic Lupus Erythematosus
Current Medicinal Chemistry AMPA Receptor Antagonists: Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Clinical Features and Disease Damage Risk Factors in an Egyptian SLE Cohort: A Multicenter Study
Current Rheumatology Reviews Screening of Candidate Pathogenic Genes for Spontaneous Abortion Using Whole Exome Sequencing
Combinatorial Chemistry & High Throughput Screening Pathologic Findings of Autoimmune Pancreatitis and IgG4-Related Disease
Current Immunology Reviews (Discontinued) Dye Visualization - A Method for Investigating Biomechanical Flows
Current Pharmaceutical Biotechnology An Overview of Current Advances in Contemporary Percutaneous Coronary Intervention
Current Cardiology Reviews Emerging Therapies for Dyslipidemia: Known Knowns and Known Unknowns of MTP Inhibitors
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Cellular and Molecular Mechanisms of Antithrombogenic Plants: A Narrative Review
Current Pharmaceutical Design Principles of Clinical Management of Patent Ductus Arteriosus in Extremely Preterm Neonates
Current Pediatric Reviews P-Selectin Antagonism in Inflammatory Disease
Current Pharmaceutical Design